Evidence map›Paper›PMID 30718433›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Most viral peptides displayed by class I MHC on infected cells are immunogenic.

Nathan P Croft, Stewart A Smith, Jana Pickering, John Sidney, Bjoern Peters, Pouya Faridi, Matthew J Witney, Prince Sebastian, Inge E A Flesch, Sally L Heading and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 134 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Structural and physical features that distinguish tumor-controlling from inactive cancer neoepitopes.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Nathan P CroftInfection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; nathan.croft@monash.edu anthony.purcell@monash.edu david.tscharke@anu.edu.au.ORCID 0000-0002-2128-5127
Stewart A SmithJohn Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
Jana PickeringJohn Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037.
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037.
Pouya FaridiInfection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Matthew J WitneyJohn Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
Prince SebastianJohn Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
Inge E A FleschJohn Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
Sally L HeadingJohn Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037.
Nicole L La GrutaInfection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia.
Anthony W PurcellInfection and Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia; nathan.croft@monash.edu anthony.purcell@monash.edu david.tscharke@anu.edu.au.ORCID 0000-0003-0532-8331
David C TscharkeJohn Curtin School of Medical Research, The Australian National University, Canberra, ACT 2601, Australia; nathan.croft@monash.edu anthony.purcell@monash.edu david.tscharke@anu.edu.au.ORCID 0000-0001-6825-9172
Australian National University · AUAustralian Regenerative Medicine Institute · AULa Jolla Institute for Immunology · USThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD8

Indexed as

AnimalsAntibody FormationAntigen PresentationCD8-Positive T-LymphocytesHistocompatibility Antigens Class IHumansImmunity, CellularImmunogenetic PhenomenaLymphocyte ActivationMicePeptidesT-Lymphocytes, CytotoxicVaccinia virusHistocompatibility Antigens Class IPeptidesantigen presentationCD8+ T cellsMHC class Ivaccinia virusvirus

Identifiers

PMID30718433
PMCPMC6386720
OpenAlexW2912018962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.